Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > Replicel - Trading Halt Recinded

<< Previous

Bullboard Posts

Next >>

Comment by Ingiboyon Oct 19, 2024 12:32pm

64 Views

Post# 36273120

RE:RE:Replicel - Trading Halt Recinded

Tuesday morning will be very interesting. I think the recinding of the trading halt might be a necessary step in this takeover bid.

The biggest question for me is what type of trading will take place ?
What will the bid/ask be ?
Will there big volume or not ?

I think there will be a number of shareholdersare totally fed up with what is going on and take the opportunity to liquidate at any price.

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement